id,group_id,source,exact,prefix,suffix,anno_type,position_type,start,end,tags,all,origin_tags,comment,user,title,created
zxiwnqlDEemg3ystR6Zi1w,jgraPEon,https://europepmc.org/articles/PMC5607173/,breast cancer ,", University of Birmingham. The ",cell line MDA-MB-231 was provide,TextQuoteSelector,TextPositionSelector,16298,16312,WS_DS,yes,[WS_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:07:10.976002+00:00
z1j8zrQNEemKuMPCN_9rQw,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17 has been implicated in the response to BCG immunotherapy in a murine bladder cancer , on the disease setting [20–24].,"model [25]; however, there are n",TextQuoteSelector,TextPositionSelector,20551,20642,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:38:21.482380+00:00
yw7q8rQNEemj38N3fcMI6Q,jgraPEon,https://europepmc.org/articles/PMC5607173/,"bladder cancer microenvironment contains CD3+ T cells, FoxP3+ cells, CD68+ macrophages and CD15+ granulocytes. B: Representative images from two bladder cancer biopsies with high (left) or low (right) numbers of IL-17",or the primary antibody. A: The , positive cells present. Note th,TextQuoteSelector,TextPositionSelector,19907,20124,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:38:14.388829+00:00
ys7kPqlFEemTwAvX54vCvw,jgraPEon,https://europepmc.org/articles/PMC5607173/,rheumatoid arthritis ,sites of active inflammation in ,"[45–47], psoriasis [48] and athe",TextQuoteSelector,TextPositionSelector,41248,41269,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:21:23.011221+00:00
xVeIMLQNEempcvd0ujuN4Q,jgraPEon,https://europepmc.org/articles/PMC5607173/," IL-17-receptor in bladder tumours, and functional effects and gene expression changes induced by IL-17 in bladder tumour", tumour types. Expression of the, cells in vitro suggest a role i,TextQuoteSelector,TextPositionSelector,11304,11425,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:38:04.633915+00:00
xQ4XIqlFEemwk5f05ryHng,jgraPEon,https://europepmc.org/articles/PMC5607173/,oesophageal cancer, the survival advantage seen in ," [44]; one possibility, therefor",TextQuoteSelector,TextPositionSelector,40753,40771,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:21:13.195176+00:00
wnbt4LQNEemak0s_dIQHfg,jgraPEon,https://europepmc.org/articles/PMC5607173/, tumour immunophenotype identified IL-17, Further characterisation of the,+ cells as predominantly mast ce,TextQuoteSelector,TextPositionSelector,11150,11190,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:37:59.838498+00:00
v56SWLQNEemviYvRltVC_A,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17-positive cells were significantly increased in primary and concomitant carcinoma,p for 4.33±1.71 years. We found ," in situ (CIS), p<0.0001, a high",TextQuoteSelector,TextPositionSelector,10907,10993,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:37:55.106913+00:00
v3TnRqlFEempedNzujmp_g,jgraPEon,https://europepmc.org/articles/PMC5607173/,oesophageal squamous cell carcinoma,-keeping with a recent study in , where IL-17+ MCs were also iden,TextQuoteSelector,TextPositionSelector,40377,40412,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:21:03.935751+00:00
usI0PqlEEemPh3OQIQiskA,jgraPEon,https://europepmc.org/articles/PMC5607173/,MIBC,muscle-invasive bladder cancer (,: stages T2+) occurs in up to 45,TextQuoteSelector,TextPositionSelector,12677,12681,MIS_DS,yes,[MIS_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:13:46.466492+00:00
thBfTKlEEemixQduz6w1MQ,jgraPEon,https://europepmc.org/articles/PMC5607173/,muscle-invasive bladder cancer ,of patients [4]. Progression to ,(MIBC: stages T2+) occurs in up ,TextQuoteSelector,TextPositionSelector,12645,12676,WS_DS,no,WS_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:13:38.680831+00:00
t_w-GKlHEemL0S8f_JIYzQ,jgraPEon,https://europepmc.org/articles/PMC5607173/,ELANE,itive for MC tryptase (MCT). No ,-positive neutrophils were prese,TextQuoteSelector,TextPositionSelector,32948,32953,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:35:10.305522+00:00
tWb2SKlCEemwgr_zsXofig,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17,on the disease setting [20–24]. , has been implicated in the resp,TextQuoteSelector,TextPositionSelector,20552,20557,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T09:59:18.526590+00:00
tGyPDqlDEem6uo9bVPrW4w,jgraPEon,https://europepmc.org/articles/PMC5607173/,Cancer , were obtained from the Bladder ,Prognosis Programme (BCPP—clinic,TextQuoteSelector,TextPositionSelector,14824,14831,WT_DS,no,[WT_DS],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:06:26.360190+00:00
t2oBnqlFEemRY19ecoklBA,jgraPEon,https://europepmc.org/articles/PMC5607173/, gastric cancer,association recently observed in," [23]. Paradoxically, CIS patien",TextQuoteSelector,TextPositionSelector,40117,40132,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:20:50.347500+00:00
sGsixLQNEemviDeRFGMl1Q,jgraPEon,https://europepmc.org/articles/PMC5607173/,"cancer [44]; one possibility, therefore, is that BCG amplifies the beneficial effects associated with increased numbers of IL-17",l advantage seen in oesophageal ,"+ MCs.Currently, we can only spe",TextQuoteSelector,TextPositionSelector,40765,40893,NGD,no,NGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:37:29.571640+00:00
rTY86KlEEemJaVvI_EQYTw,jgraPEon,https://europepmc.org/articles/PMC5607173/,pT1,"time of diagnosis (pTa, n = 17; ",", n = 10; T2+, n = 8; CIS, n = 8",TextQuoteSelector,TextPositionSelector,22118,22121,WT_GP,yes,[WT_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:13:23.844002+00:00
qbbdQqlFEempeF-_GJZrfg,jgraPEon,https://europepmc.org/articles/PMC5607173/,bear ,directly upon tumour cells that ,IL-17R [42]. Since we found that,TextQuoteSelector,TextPositionSelector,38187,38192,WT_OG,no,[WT_OG],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:20:27.486648+00:00
qJAF4rQNEemR_Re9nlB9Jg,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17 staining into standard histopathological tumour , in UBC patients. Incorporating ,"assessment, or potentially inclu",TextQuoteSelector,TextPositionSelector,44595,44649,NGD,no,NGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:37:16.327918+00:00
p4-gLKlEEembyK9r-5QfoA,jgraPEon,https://europepmc.org/articles/PMC5607173/,carcinoma in situ,a.IL-17+ cells are increased in ,The marked differences observed ,TextQuoteSelector,TextPositionSelector,21054,21071,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:13:14.365279+00:00
ow77tLQNEemGNh-fdth1QQ,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17+ MCs in patients by utilising the long-term outcome data linked to the tumour, to identify the consequences of, samples. We acknowledge that su,TextQuoteSelector,TextPositionSelector,39583,39667,NGD,no,NGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:37:07.168216+00:00
o1UGVKlFEem0egP25hzMhA,jgraPEon,https://europepmc.org/articles/PMC5607173/,tumorigenesis ,"31,32]. Conversely, MCs enhance ","and angiogenesis [33–35], and ha",TextQuoteSelector,TextPositionSelector,37477,37491,WT_DS,no,[WT_DS],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:20:16.580170+00:00
o0nsYqlDEemTSJ-IIl-Y9Q,jgraPEon,https://europepmc.org/articles/PMC5607173/,cancer ,ment is considered to influence ,behaviour and outcome. Using a p,TextQuoteSelector,TextPositionSelector,10597,10604,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:05:57.551792+00:00
nk1Q9KlEEemx4VP7ZlbA9Q,jgraPEon,https://europepmc.org/articles/PMC5607173/,CD68 ,"3 (to identify T cell subsets), ",(to identify macrophages) or CD1,TextQuoteSelector,TextPositionSelector,30505,30510,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:12:58.722973+00:00
ndGRKqlFEemN-h-TNL0BMA,jgraPEon,https://europepmc.org/articles/PMC5607173/,MC tryptase ,ins MCs that stain positive for ,(MCT). No ELANE-positive neutrop,TextQuoteSelector,TextPositionSelector,32926,32938,WS_GP,no,WS_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:20:07.419291+00:00
nMN6eLQNEem23Wf_k8oYwQ,jgraPEon,https://europepmc.org/articles/PMC5607173/," tumour, the IL-17",ency and distribution within the,+ cells were clearly not T cells,TextQuoteSelector,TextPositionSelector,36945,36963,NGD,no,NGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:36:56.623312+00:00
mzwa4qlGEemOAbMWaA4aRA,jgraPEon,https://europepmc.org/articles/PMC5607173/,Interleukin-17,1PMCID: PMC5607173PMID: 28931051,-positive mast cells influence o,TextQuoteSelector,TextPositionSelector,6130,6144,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:27:12.515401+00:00
mBQLyLQNEemdKFOkqIb7fw,jgraPEon,https://europepmc.org/articles/PMC5607173/, tumour specimen stained for IL-17 ,s a serial section from the same,alone (red) for comparison. The ,TextQuoteSelector,TextPositionSelector,33596,33631,NGD,no,NGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:36:48.818832+00:00
lu1u0KlDEemak__OADYQhA,jgraPEon,https://europepmc.org/articles/PMC5607173/,urothelial bladder cancer, the immune microenvironment of ,"Alexander C. Dowell, Conceptuali",TextQuoteSelector,TextPositionSelector,6293,6318,WS_DS,yes,[WS_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:05:36.955654+00:00
krwCnqlEEemS9McF4JupGQ,jgraPEon,https://europepmc.org/articles/PMC5607173/,CLS,".. E: Growth of EJ, 5637 and HB-",-2 cells after five days incubat,TextQuoteSelector,TextPositionSelector,26798,26801,WT_GP,yes,[WT_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:12:39.298448+00:00
kc1znrQNEem2BLcgwgL28w,jgraPEon,https://europepmc.org/articles/PMC5607173/,"bladder cancer biopsy, in this case CIS, stained with a primary antibody specific for the IL-17",sentative result obtained for a , receptor (brown staining repres,TextQuoteSelector,TextPositionSelector,25889,25984,NGD,no,NGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:36:38.308643+00:00
kJdZ0KlGEemGYZuA3B9vkw,jgraPEon,https://europepmc.org/articles/PMC5607173/,atherosclerotic plaques ,"tis [45–47], psoriasis [48] and ","[49]. Furthermore, inflammatory ",TextQuoteSelector,TextPositionSelector,41297,41321,MIS_DS,no,MIS_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:26:54.787642+00:00
jjvU5qlFEemwkIsU4hk6Rg,jgraPEon,https://europepmc.org/articles/PMC5607173/,mast cell tryptase, of neutrophils (ELANE) or MCs (,", MCT). We saw little or no ELAN",TextQuoteSelector,TextPositionSelector,31077,31095,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:19:41.384819+00:00
jIduRLQNEembZeeQuurrEA,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17 receptor expression and function in bladder cancer,).Open in a separate windowFig 3,.A: Representative result obtain,TextQuoteSelector,TextPositionSelector,25792,25848,NGD,no,NGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:36:29.491472+00:00
iyPiXqlEEemlWjeBFVxL2g,jgraPEon,https://europepmc.org/articles/PMC5607173/,human,gue that it is more relevant to , health since it takes into acco,TextQuoteSelector,TextPositionSelector,39812,39817,CRT_OG,yes,[CRT_OG][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:12:26.527915+00:00
iAFunKlFEemTHasPOG1bWA,jgraPEon,https://europepmc.org/articles/PMC5607173/,growth factor ,S1 File). Genes associated with ,activity were increased and sign,TextQuoteSelector,TextPositionSelector,29419,29433,WT_GP,no,[WT_GP],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:19:30.783743+00:00
gslrKLQNEem-p2fjEC0yWw,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17 on three bladder cancer,e examined the direct effect of ," cell lines (EJ, 5637 and HB-CLS",TextQuoteSelector,TextPositionSelector,24801,24830,NGD,no,NGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:36:13.156260+00:00
g5GotKlEEemTFhMeGCVZkg,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-6 ,"of (C) IL-17A, (D) IL-17-F, (E) ",or (F) IL-23 are shown relative ,TextQuoteSelector,TextPositionSelector,22503,22508,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:12:13.819431+00:00
fIK8lKlDEemibl8zPLgylw,jgraPEon,https://europepmc.org/articles/PMC5607173/,bladder cancer ,entre cohort of newly-diagnosed ,"patients, followed-up for 4.33±1",TextQuoteSelector,TextPositionSelector,10840,10855,WS_DS,yes,[WS_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:04:52.522150+00:00
fBHPxqlCEemrCQOLPLUeBA,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17,up for 4.33±1.71 years. We found,-positive cells were significant,TextQuoteSelector,TextPositionSelector,10906,10912,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T09:57:42.299083+00:00
f0SZeKlFEemix6d9XA42oA,jgraPEon,https://europepmc.org/articles/PMC5607173/,cytokine ,ased mRNA levels of the related ,"IL-17F as well as IL-6, the expr",TextQuoteSelector,TextPositionSelector,23687,23696,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:19:16.134577+00:00
ezGcoLQNEemkS7t9GUnYfw,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17 on bladder tumours,etermine the effect of elevated ,". First, we stained 14 bladder c",TextQuoteSelector,TextPositionSelector,24420,24444,NGD,no,NGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:36:00.252611+00:00
enBECqlGEem6wftgSlo-RA,jgraPEon,https://europepmc.org/articles/PMC5607173/,NIMBC ,r biopsy RNA from patients with ,grade 3 disease with or without ,TextQuoteSelector,TextPositionSelector,23216,23222,MIS_DS,no,MIS_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:26:17.515014+00:00
e61zZqlFEemhqbccw1CdFQ,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17F, levels of the related cytokine ," as well as IL-6, the expression",TextQuoteSelector,TextPositionSelector,23696,23702,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:19:10.129754+00:00
cTtexKlGEemhsq_9DcHbsw,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-23,"A, (D) IL-17-F, (E) IL-6 or (F) ", are shown relative to GAPDH (ΔC,TextQuoteSelector,TextPositionSelector,22515,22520,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:26:02.114543+00:00
bg8zRKlEEem6vM_bgAFvNA,jgraPEon,https://europepmc.org/articles/PMC5607173/,tumours, IL-17+ cells were from grade 3 ,"; however, not all grade 3 tumou",TextQuoteSelector,TextPositionSelector,21458,21465,MIS_DS,yes,[MIS_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:11:37.877161+00:00
awY6_KlFEemixmdDpugxbw,jgraPEon,https://europepmc.org/articles/PMC5607173/,GAPDH ,(F) IL-23 are shown relative to ,(ΔCT = CTExperimental-CTGAPDH). ,TextQuoteSelector,TextPositionSelector,22543,22549,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:18:42.199763+00:00
avP6dqlGEemwpwuXrxXE8A,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17-F," transcripts of (C) IL-17A, (D) ",", (E) IL-6 or (F) IL-23 are show",TextQuoteSelector,TextPositionSelector,22490,22497,WS_GP,no,WS_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:25:51.570548+00:00
_Qq4krQNEempy6ODwkkDsw,jgraPEon,https://europepmc.org/articles/PMC5607173/,"bladder cancer cell lines were responsive to IL-17, as demonstrated by increased production of IL-6 and IL-8", same level (Fig 3B). All three ," (Fig 3C and 3D). However, subse",TextQuoteSelector,TextPositionSelector,24934,25042,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:39:38.269155+00:00
_8dM7rQNEemjwtcG58bACg,jgraPEon,https://europepmc.org/articles/PMC5607173/," cancer cell lines showing IL-17 to enhance cell migration [24], as demonstrated by the breast cancer ",ntrast to previous work on other,control cell line included in ou,TextQuoteSelector,TextPositionSelector,25601,25703,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:39:42.740188+00:00
_5r87qlEEemDFr8cVcIx2w,jgraPEon,https://europepmc.org/articles/PMC5607173/,bladder cancers ,. In Western populations 90% of ,are transitional cell carcinoma ,TextQuoteSelector,TextPositionSelector,12267,12283,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:15:42.071481+00:00
Zqr6lKlDEem55ytbO-P0og,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17R,IL-17R [42]. Since we found that, was expressed by many bladder t,TextQuoteSelector,TextPositionSelector,38224,38231,WS_GP,yes,[WS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:04:15.872972+00:00
ZlMVDKlFEemwj0t7K9n7vA,jgraPEon,https://europepmc.org/articles/PMC5607173/,GAPDH,o GAPDH (ΔCT = CTExperimental-CT,). Asterisks indicate significan,TextQuoteSelector,TextPositionSelector,22573,22578,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:18:34.421973+00:00
ZcaNmKlGEem6IlcnFFG7Aw,jgraPEon,https://europepmc.org/articles/PMC5607173/,CD4,"uted to Th17 cells, a subset of ","+ T cells, although other immune",TextQuoteSelector,TextPositionSelector,20357,20360,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:25:42.898258+00:00
YNZf1KlGEemMxq8cwfb3ag,jgraPEon,https://europepmc.org/articles/PMC5607173/,TCRγ,regulatory T cells) and innate (,", γδT cells; CD15, granulocytes;",TextQuoteSelector,TextPositionSelector,18732,18736,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:25:34.518737+00:00
Xoh0MrRQEem6lWeMHoaQmA,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17-receptor,tumour types. Expression of the ," in bladder tumours, and functio",TextQuoteSelector,TextPositionSelector,11292,11306,WS_GP,yes,[WS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T11:34:48.570188+00:00
XU7MiqlFEem5dbuncoQqrw,jgraPEon,https://europepmc.org/articles/PMC5607173/,CD15,"s) and innate (TCRγ, γδT cells; ",", granulocytes; CD68, macrophage",TextQuoteSelector,TextPositionSelector,18749,18753,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:18:19.309863+00:00
WRsYIqlEEemDE7tgzYacng,jgraPEon,https://europepmc.org/articles/PMC5607173/,tumours,rate can vary between different ," [6,7]. With regard to NMIBC, th",TextQuoteSelector,TextPositionSelector,14001,14008,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:11:02.744066+00:00
W8fxYKlGEemGYEv9rTV8-g,jgraPEon,https://europepmc.org/articles/PMC5607173/,FoxP3,"of the adaptive, (CD3, T cells; ",", regulatory T cells) and innate",TextQuoteSelector,TextPositionSelector,18693,18698,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:25:26.141410+00:00
Vn7uqKlFEemhqG9KEfTYNQ,jgraPEon,https://europepmc.org/articles/PMC5607173/,CD3, shown in Fig 1. Infiltrates of ,+ T-cells were mostly present in,TextQuoteSelector,TextPositionSelector,18882,18885,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:18:07.739510+00:00
U5fA7KlGEempfBu2qPsPOg,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17 receptor ,).Open in a separate windowFig 3,expression and function in bladd,TextQuoteSelector,TextPositionSelector,25792,25807,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:25:12.475699+00:00
TxFJNqlFEemzePcPBUi8nA,jgraPEon,https://europepmc.org/articles/PMC5607173/,Infiltrates ,is analysis are shown in Fig 1. ,of CD3+ T-cells were mostly pres,TextQuoteSelector,TextPositionSelector,18867,18879,WT_DS,no,[WT_DS],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:17:55.267657+00:00
TB11wKlEEem8l7_Z18GEQQ,jgraPEon,https://europepmc.org/articles/PMC5607173/,bladder tumours,n absence of γδT cells in human ,", we propose an alternative scen",TextQuoteSelector,TextPositionSelector,42858,42873,WS_DS,yes,[WS_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:10:40.856870+00:00
SOZ25KlFEeme6m-TmmRp5w,jgraPEon,https://europepmc.org/articles/PMC5607173/,mycoplasma,0.1 mg/ml streptomycin (Sigma); , testing was carried out on rece,TextQuoteSelector,TextPositionSelector,16533,16543,"WT_DS,OG",no,[WT_DS][OG],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:17:44.917910+00:00
SEzBdKlGEemTwpP2TiLnIw,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17 receptor,col. Cell surface levels of the , (IL-17R) were measured by flow ,TextQuoteSelector,TextPositionSelector,17503,17517,WS_GP,yes,[WS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:24:53.449787+00:00
QtQ15KlEEemMsduj3NwGCg,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-8,ncreased production of IL-6 and ,. Gene expression analysis revea,TextQuoteSelector,TextPositionSelector,39214,39218,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:10:25.259662+00:00
Qk88EqlFEem6v0NmL3d8pw,jgraPEon,https://europepmc.org/articles/PMC5607173/,bovine,um supplemented with 10% foetal ," serum, 100 U/ml penicillin and ",TextQuoteSelector,TextPositionSelector,16463,16469,WT_OG,no,[WT_OG],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:17:33.833102+00:00
Pvf06rQOEemxo0PG0S7MyA,jgraPEon,https://europepmc.org/articles/PMC5607173/,"IL-17, inducing IL-8 production by urothelium and, as we have shown, tumour",cited via MCs rapidly releasing , cells recruiting increased numb,TextQuoteSelector,TextPositionSelector,43005,43080,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:41:28.741511+00:00
OzIyLKlFEeme6UfZYMLHgA,jgraPEon,https://europepmc.org/articles/PMC5607173/,alkaline phosphatase, in S2 File) and HRP-DAB and/or ,-vector red enzyme-substrate com,TextQuoteSelector,TextPositionSelector,15507,15527,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:17:22.048021+00:00
Ocg7JLQOEemalJvc3WiaMw,jgraPEon,https://europepmc.org/articles/PMC5607173/,"IL-17 in place of murine MCs [19]; consistently, γδT cells produce IL-17 in response to BCG in a murine model of bladder cancer ",udies suggest γδT cells produce ,"[25]. In this model, IL-17 was r",TextQuoteSelector,TextPositionSelector,42422,42550,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:41:20.048234+00:00
OUph7KlEEemx3u-o2EXJ5Q,jgraPEon,https://europepmc.org/articles/PMC5607173/,MCT,"NE) or MCs (mast cell tryptase, ",). We saw little or no ELANE sta,TextQuoteSelector,TextPositionSelector,31097,31100,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:10:09.188038+00:00
NpGT9rQOEemicTfQcuYVfw,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17+ MCs at sites of active inflammation,imuli. Reports have demonstrated, in rheumatoid arthritis [45–47],TextQuoteSelector,TextPositionSelector,41201,41244,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:41:14.729762+00:00
NYyZKqlFEemlX1duwYL9ig,jgraPEon,https://europepmc.org/articles/PMC5607173/,HRP,bodies (Table A in S2 File) and ,-DAB and/or alkaline phosphatase,TextQuoteSelector,TextPositionSelector,15492,15495,WT_GP,no,[WT_GP],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:17:12.489533+00:00
MpTlZLQOEemj4K_hcM2Rqw,jgraPEon,https://europepmc.org/articles/PMC5607173/," IL-17 vary markedly, even within the context of a single tumour",trate that the direct effects of, type.Although these in vitro ef,TextQuoteSelector,TextPositionSelector,39422,39486,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:41:08.077492+00:00
LWaGBqlGEem-zldz6bUrkw,jgraPEon,https://europepmc.org/articles/PMC5607173/,UBCs ,ples of newly-diagnosed primary ,were obtained from the Bladder C,TextQuoteSelector,TextPositionSelector,14788,14793,MIS_DS,no,MIS_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:24:08.350602+00:00
LFPwvrQOEemAaOvk8qAphw,jgraPEon,https://europepmc.org/articles/PMC5607173/," IL-17 increased the growth rate of 5637 cells, concurring with previously published work examining the MB49 murine bladder cancer",ression in different cell lines.," cell in mice [42]. Furthermore,",TextQuoteSelector,TextPositionSelector,38489,38619,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:40:57.444007+00:00
LAS7-KlFEemWNMeIf5_Gcw,jgraPEon,https://europepmc.org/articles/PMC5607173/,BCG,sical Bacillus Calmette-Guerin (,) immunotherapy in a regimen of ,TextQuoteSelector,TextPositionSelector,13311,13314,MIS_OG,yes,[MIS_OG][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:16:56.564136+00:00
L7kVhrQOEem23i-hGqm-iw,jgraPEon,https://europepmc.org/articles/PMC5607173/,"bladder cancer cell lines that we studied was not significantly affected by IL-17, despite eliciting a response by increased production of IL-6 and IL-8","ntrast, growth of the other two ",. Gene expression analysis revea,TextQuoteSelector,TextPositionSelector,39066,39218,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:41:03.155697+00:00
L5RskqlEEemcLPuEhSLZYw,jgraPEon,https://europepmc.org/articles/PMC5607173/,bladder tumour ,ion changes induced by IL-17 in ,cells in vitro suggest a role in,TextQuoteSelector,TextPositionSelector,11411,11426,WS_DS,yes,[WS_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:09:53.083782+00:00
KRGZurQOEemPoWd1t2Tsjw,jgraPEon,https://europepmc.org/articles/PMC5607173/," tumours, we decided to focus on the potential direct effects of IL-17 ",7R was expressed by many bladder,on bladder cancer cells. IL-17 i,TextQuoteSelector,TextPositionSelector,38261,38332,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:40:52.122781+00:00
JQTFVLQOEempzQ_7ISo_cw,jgraPEon,https://europepmc.org/articles/PMC5607173/," IL-17 can act indirectly (for example, promoting tumour",come in the UBC setting.Although, growth by altering the immune m,TextQuoteSelector,TextPositionSelector,38028,38084,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:40:45.299899+00:00
JIYRuqlFEemx5IPdjGeqOQ,jgraPEon,https://europepmc.org/articles/PMC5607173/,Bacillus Calmette-Guerin,repeated cycles of intravesical , (BCG) immunotherapy in a regime,TextQuoteSelector,TextPositionSelector,13285,13309,CRT_OG,no,CRT_OG,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:16:43.893029+00:00
If5HLLQOEemPn6u4r8WR0g,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17 knockout mice some tumours ,f IL-17 in cancer is complex. In,"grow more rapidly, whilst others",TextQuoteSelector,TextPositionSelector,37633,37667,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:40:39.842594+00:00
HoCWKKlFEemic0OjneamSw,jgraPEon,https://europepmc.org/articles/PMC5607173/,dysplasia ,(CIS) [8]. This flat high-grade ,is highly malignant with signifi,TextQuoteSelector,TextPositionSelector,13085,13095,WT_DS,no,[WT_DS],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:16:33.798905+00:00
Hk5qvLQOEemvjN9aya_aiw,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17 in cancer,"y [36,37]. Likewise, the role of", is complex. In IL-17 knockout m,TextQuoteSelector,TextPositionSelector,37602,37618,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:40:33.968524+00:00
GrJvKrQOEem787sdkiL1vw,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17+ cells in their tumours,t some patients with CIS had few,", suggesting their presence was ",TextQuoteSelector,TextPositionSelector,36703,36733,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:40:27.981598+00:00
GRy84qlGEemmFW-8hKI0_w,jgraPEon,https://europepmc.org/articles/PMC5607173/,bladder CIS,dentify the IL-17+ cell type in ,", we optimised the immunostainin",TextQuoteSelector,TextPositionSelector,30350,30361,MIS_DS,yes,[MIS_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:23:34.360414+00:00
Fq1PJrQOEemE6qOAdYq34Q,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17+ cells between different patients’ tumours,ked variation in the numbers of ,", with increased numbers of thes",TextQuoteSelector,TextPositionSelector,36519,36567,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:40:21.152381+00:00
Ffz4HKlEEemg5fPxEqqYUg,jgraPEon,https://europepmc.org/articles/PMC5607173/,tumour, within the context of a single , type.Although these in vitro ef,TextQuoteSelector,TextPositionSelector,39480,39486,WS_DS,no,WS_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:09:09.980342+00:00
FExy-KlFEemwohvehTYQcg,jgraPEon,https://europepmc.org/articles/PMC5607173/,UBC,"gin (urothelial bladder cancer, ",) and most patients (75–85%) pre,TextQuoteSelector,TextPositionSelector,12364,12367,MIS_DS,yes,[MIS_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:16:16.691917+00:00
EzIl4rQOEembZuPUmX5IgQ,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17 has been implicated in the efficacy of BCG immunotherapy in a murine bladder cancer ,"the remainder (Fig 5A). However,",model [25]; although patients wi,TextQuoteSelector,TextPositionSelector,34389,34480,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:40:15.413815+00:00
DzUnoLQOEempzOsFOtr1PA,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17 were observed in all cases confirming that MCs are the main source of IL-17 in the tumour, cells positive for both MCT and, microenvironment of bladder CIS,TextQuoteSelector,TextPositionSelector,31899,31995,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:40:08.724716+00:00
CcMjTKlIEemx8rOzvl8Ayw,jgraPEon,https://europepmc.org/articles/PMC5607173/,cytokines," Importantly, of the predictive ",", two are induced by IL-17 (IL-6",TextQuoteSelector,TextPositionSelector,43668,43677,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:37:27.516925+00:00
C3NJxrQOEemhyN99MzxPLQ,jgraPEon,https://europepmc.org/articles/PMC5607173/, inflammatory response and cell adhesion were downregulated by IL-17," contrast, genes involved in the", treatment.Mast cells constitute,TextQuoteSelector,TextPositionSelector,29686,29754,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:40:02.420936+00:00
BhJ2pqlFEem8mSPlTU5hvA,jgraPEon,https://europepmc.org/articles/PMC5607173/,transitional cell carcinoma,ions 90% of bladder cancers are , of urothelial origin (urothelia,TextQuoteSelector,TextPositionSelector,12287,12314,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:15:52.855700+00:00
BItKyLQOEemr0LelH4TBbQ,jgraPEon,https://europepmc.org/articles/PMC5607173/," breast cancer cell line MBA-MD231, which is more invasive in response to IL-17",or 48 hours before wounding. The,", was included as a positive con",TextQuoteSelector,TextPositionSelector,27268,27347,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:39:50.651049+00:00
B4_57rQOEemR_psAUGJtiw,jgraPEon,https://europepmc.org/articles/PMC5607173/,bladder cancer cell lines exposed to IL-17,henotype exhibited by different , led us to perform microarray an,TextQuoteSelector,TextPositionSelector,28053,28095,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:39:55.771841+00:00
9cnr_KlFEemaoBsX0bY_gA,jgraPEon,https://europepmc.org/articles/PMC5607173/,CIS ,hom almost half had concomitant ,"[57]. Importantly, of the predic",TextQuoteSelector,TextPositionSelector,43627,43631,MIS_DS,yes,[MIS_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:22:35.012497+00:00
9Zz2sqlDEempcwMUIByyFA,jgraPEon,https://europepmc.org/articles/PMC5607173/,tumour,dely distributed throughout the ," than T cells. Interestingly, we",TextQuoteSelector,TextPositionSelector,19272,19278,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:08:15.781349+00:00
9W93RLQNEemkTCfmwpbZNg,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17 on bladder cancer ," cells [27,28].Direct effects of",cells in vitroWe next considered,TextQuoteSelector,TextPositionSelector,23959,23984,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:39:25.372454+00:00
9P0nTqlEEemffbNoKySxqA,jgraPEon,https://europepmc.org/articles/PMC5607173/,non-muscle invasive bladder cancer, patients (75–85%) present with , (NMIBC: stages Ta/T1/Tis) [3]. ,TextQuoteSelector,TextPositionSelector,12409,12443,WS_DS,no,WS_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:15:24.171250+00:00
8eprprQNEemxohti7HEphQ,jgraPEon,https://europepmc.org/articles/PMC5607173/," tumour and stromal cells were present in excess, we detected increased IL-17",ur microenvironment. Even though, mRNA transcripts in samples fro,TextQuoteSelector,TextPositionSelector,23348,23425,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:39:19.111742+00:00
7nVG2rQNEem_PhNec-arpQ,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17 positive cells present in different bladder cancer,tage.Upper panels: The number of, biopsies are displayed accordin,TextQuoteSelector,TextPositionSelector,21910,21967,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:39:13.761187+00:00
7f3yFqlEEemwiWfb24Ni0A,jgraPEon,https://europepmc.org/articles/PMC5607173/, mouse ,ered by a lack of a suitable CIS,"model [51,52], and fundamental d",TextQuoteSelector,TextPositionSelector,42109,42116,CRT_OG,yes,[CRT_OG][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:15:12.541999+00:00
6KAyTLQNEemKdDdXDY1fQQ,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17 positive cells and bladder cancer , windowFig 2Association between ,grade and stage.Upper panels: Th,TextQuoteSelector,TextPositionSelector,21827,21867,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:39:03.838784+00:00
5J7R7qlFEemLy6-RnkpQ5Q,jgraPEon,https://europepmc.org/articles/PMC5607173/,reverse transcriptase,f primers used for quantitative , PCR.(DOCX)Click here for additi,TextQuoteSelector,TextPositionSelector,46134,46155,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:22:06.074286+00:00
5-rCtKlEEemTGFsHqZdaEw,jgraPEon,https://europepmc.org/articles/PMC5607173/,mice,r is complex. In IL-17 knockout ," some tumours grow more rapidly,",TextQuoteSelector,TextPositionSelector,37649,37653,CRT_OG,yes,[CRT_OG][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:15:02.176584+00:00
4oIlQqlEEemDFU-Ba0OhVA,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17A,lar intervals. Recombinant human," (Peprotech, UK) was added as de",TextQuoteSelector,TextPositionSelector,16622,16629,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:14:53.256684+00:00
4BOPyrQNEemzODP_bccevA,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17+ cells were from grade 3 tumours,sample with elevated numbers of ,"; however, not all grade 3 tumou",TextQuoteSelector,TextPositionSelector,21427,21465,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:38:49.529746+00:00
46DgAKlCEemvNI-i0MQ3gg,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17R,e levels of the IL-17 receptor (,) were measured by flow cytometr,TextQuoteSelector,TextPositionSelector,17519,17525,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:00:36.161677+00:00
44mqhrQNEemKc-saBf7MrA,jgraPEon,https://europepmc.org/articles/PMC5607173/, tumours at time of diagnosis demonstrated that there was a significant increase in IL-17, 2A). Examining the stage of the,+ cells in CIS patients (p = <0.,TextQuoteSelector,TextPositionSelector,21573,21662,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:38:55.351558+00:00
3UrPBqlFEemlYhdeD3pb5g,jgraPEon,https://europepmc.org/articles/PMC5607173/,humans,pose an alternative scenario in ,. We suggest that the immediate ,TextQuoteSelector,TextPositionSelector,42913,42919,CRT_OG,no,CRT_OG,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:21:53.905684+00:00
3E5OjrQNEemfcuPbwxK4lA,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17+ cell infiltrate led us to stain more tumour,ces observed in the frequency of, specimens (n = 48). All biopsy ,TextQuoteSelector,TextPositionSelector,21122,21173,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:38:43.316652+00:00
2uKbsKlDEemalpfpQDwjJw,jgraPEon,https://europepmc.org/articles/PMC5607173/,Human ,listed in Table C in S2 File. A ,Genome U133 Plus 2.0 Array (Affy,TextQuoteSelector,TextPositionSelector,17951,17957,WT_OG,no,[WT_OG],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:07:30.977598+00:00
2U_RvLQNEemPuQdmbTEpYQ,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17+ cells are increased in carcinoma ,n the surrounding tumour stroma.,in situThe marked differences ob,TextQuoteSelector,TextPositionSelector,21024,21064,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:38:38.273772+00:00
1q6qPKlFEemTIZti9TI14A,jgraPEon,https://europepmc.org/articles/PMC5607173/, toll-like receptor-2 ,shown to produce IL-17 following,ligation [50].Deeper understandi,TextQuoteSelector,TextPositionSelector,41913,41935,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:21:42.824264+00:00
1jwF8KlEEemKE_ezNjfUBw,jgraPEon,https://europepmc.org/articles/PMC5607173/,NMIBC,muscle invasive bladder cancer (,: stages Ta/T1/Tis) [3]. Patient,TextQuoteSelector,TextPositionSelector,12445,12450,MIS_DS,yes,[MIS_DS][ALL],,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:14:32.548941+00:00
1TP_QLQNEemjoycpaMx4jg,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17+ cells did not infiltrate into the tumour ,"s. When present, the majority of",but were located in the tumour m,TextQuoteSelector,TextPositionSelector,20870,20919,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:38:31.296010+00:00
0m6D6LQNEemKud-hmm9UmA,jgraPEon,https://europepmc.org/articles/PMC5607173/,IL-17 positive (IL-17+) cells in different tumour ,ere was noticeable variation in ,"biopsies. When present, the majo",TextQuoteSelector,TextPositionSelector,20781,20831,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:38:26.642957+00:00
0JtHrqlFEemhrX85Q2CsKQ,jgraPEon,https://europepmc.org/articles/PMC5607173/,psoriasis ,"n rheumatoid arthritis [45–47], ",[48] and atherosclerotic plaques,TextQuoteSelector,TextPositionSelector,41278,41288,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:21:32.623158+00:00
01kB3KlCEemTssvhAKeqBw,jgraPEon,https://europepmc.org/articles/PMC5607173/,rhIL-17, plate at 1x105 cells/well with , added for 48hrs before wounding,TextQuoteSelector,TextPositionSelector,17057,17064,WS_GP,no,WS_GP,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-18T10:00:08.798676+00:00
-M6nmLQNEemKuv9mKM7Ylw,jgraPEon,https://europepmc.org/articles/PMC5607173/, IL-17 has been reported to act directly on tumour,levated numbers of IL-17+ cells., and stromal cells that express ,TextQuoteSelector,TextPositionSelector,24091,24141,YGD,no,YGD,,acct:farheen.s@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T03:39:30.890754+00:00
